EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

NCT02475720 ·Status: COMPLETED

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

NCT05598528 ·Status: RECRUITING

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821 ·Status: RECRUITING ·Phase: PHASE2

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

NCT04207775 ·Status: COMPLETED

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 ·Status: UNKNOWN

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419 ·Status: COMPLETED ·Phase: PHASE3

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560 ·Status: COMPLETED

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

NCT02618590 ·Status: UNKNOWN

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

NCT01955681 ·Status: COMPLETED

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

NCT03856697 ·Status: UNKNOWN ·Phase: PHASE3

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

NCT03811054 ·Status: UNKNOWN ·Phase: PHASE2

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185 ·Status: UNKNOWN ·Phase: PHASE2

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NCT02140333 ·Status: UNKNOWN ·Phase: PHASE3

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

NCT05997719 ·Status: RECRUITING

Phase I, Study in Chinese NSCLC Patients

NCT02529995 ·Status: COMPLETED ·Phase: PHASE1

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

NCT03519958 ·Status: WITHDRAWN

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 ·Status: COMPLETED